Pfizer (PFE) Ticks Higher on Expanded Lyrica Indication
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Join SI Premium – FREE
Pfizer (NYSE: PFE) shares are up early following news its Lyrica caps were approved by the FDA to manage neuropathic pain associated with spinal cord injury.
The stock is up 0.6 percent in early trade.
The stock is up 0.6 percent in early trade.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- AC Immune reports early Phase 1 data for NLRP3 inhibitor ACI-19764
- Trans Canada Gold wraps up phase 1 drilling at Harrison Lake project
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
